Lundbeck
Joseph Liberman currently serves as the Neurology Field Medical Lead for Lundbeck and holds a position as Director on the Board of Directors for the Bleeding Disorder Foundation of Washington. Previously, Joseph was the Director of Field Capabilities in Global Medical and Scientific Affairs at Karyopharm Therapeutics, where responsibilities included preparing for the launch of etranacogene dezaparvovec and supporting pipeline products. Joseph has also worked as an Associate Director in Medical Affairs at uniQure, focusing on gene therapy projects, and held various roles at Takeda, covering marketed and pipeline products in hematology. Joseph's academic background includes a PhD in Biochemistry from the University of Rochester and postdoctoral research at Yale University and the University of Rochester.
This person is not in any offices
Lundbeck
43 followers
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.